All In Biotech

Drug Trial Radar · NCT05745883

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

A Phase 1b Multicenter, Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DISC-0974 in Participants With Non-Dialysis Dependent Chronic Kidney Disease and Anemia

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

Apr 4, 2023

Primary completion

Oct 9, 2025

Study completion Jan 16, 2026

Sponsor

Lead sponsor
Disc Medicine, IncIndustry
Sponsor type
Industry
First posted
Feb 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia.

Conditions

  • Chronic Kidney Diseases
  • Anemia of Chronic Kidney Disease

Interventions

  • DISC-0974Drug

    DISC-0974 is administered subcutaneously

  • PlaceboDrug

    Placebo is administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: up to 145 days
  2. Incidence of clinically abnormal vital signsTime frame: up to 145 days
  3. Incidence of abnormal laboratory test resultsTime frame: up to 145 days
  4. Incidence of clinically abnormal physical examTime frame: up to 145 days
  5. Incidence of clinically abnormal electrocardiogramsTime frame: up to 145 days

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Clinical and Translational Research

    Los Angeles, California

  • US Renal Care Inc.

    Lone Tree, Colorado

  • Accel Research

    DeLand, Florida

  • Total Research Group

    Miami, Florida

  • Flourish Research

    Winter Park, Florida

  • Nephrology and Hypertension Specialists, PC-Dalton

    Dalton, Georgia

  • CARE Institute - Boise Kidney

    Boise, Idaho

  • Center for Advanced Kidney Research PLC

    Saint Clair Shores, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Centricity Research

    Columbus, Ohio

  • Clinical Advancement Center, PLLC

    San Antonio, Texas

  • Endeavor Clinical Trials

    San Antonio, Texas

  • Washington Nephrology Associates, LLP

    Alexandria, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.